Invest, Acquire, License, Partner.Â
Sep 9-10, Boston MA
Collaborate, license, and partner across ADCs, and radiopharmaceutical pipelines to reduce risks, validate technologies, and acquire clinically ready assets
Why Now?
Major moves in the pharma and biotech partnering are reshaping the landscape. With AbbVie's acquisition of ImmunoGen leading the charge in 2023, and Merck's licensing deal with Daiichi reaching unprecedented heights across three ADC programs, the market frenzy surrounding ADCs has never been hotter.
Even Eli Lilly's acquisition of Mablink, despite lacking clinical programs, underscores the feverish pace of activity in the field, breaking traditional pharma partnering trends.Â
For ADC companies, the challenge lies in standing out, validating their offerings, and securing clinical-ready assets amidst this whirlwind of activity.
How does one differentiate and obtain assets poised for clinical success in the next wave of deals?
Enter the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit. This event cuts through the noise of partnership events to gather a targeted critical mass of 100+ ADC companies. It provides a platform for networking and fast-tracking the search and evaluation of earlier development assets. By significantly improving the alignment, efficiency, and yield of conversations, this summit empowers participants to navigate the complex partnering landscape with confidence.Â
SPEAKERS
Steven Bartz
Head of Oncology Business Development, Search & Evaluation
Pfizer
David Dowling
Global Search & Evaluation Lead, Oncology Strategy
Roche
Polly Brown
Vice President, Head of Business Development, Oncology Research & Development
AstraZeneca
Albert Hsia
Executive Director, Business Development
Merck
Jenny Wang
Director Search & Evaluation Oncology
AbbVie
Andressa Smith
Senior Director, Scientific Licensing & Acquisition, Oncology Business Development
Johnson & Johnson
Avnish Kapoor
Executive Director, Search & Evaluation, Oncology Business Development
BMS
Venky Raghavan
Executive Director Search & Evaluation Oncology
Novartis
Christopher Davies
Business Development
Project Leader
Genentech
He Tian
Associate Director of External Innovations
BioNTech
Looking to invest, acquire, license, or partner?
For large pharma business development:
Scout novel payloads or new linker conjugation chemistry with click-release tumor specificity.
Bring disruptive science in early development into in-house pipelines to stay ahead of the curve.
For investment directors and venture partners:
Identify strategic assets with compelling data packages and gain market intelligence into big pharma interests.
Ensure investments yield returns in the dynamic ADC space.Â
FOR ADC COMPANY CORPORATE DEVELOPMENT
Seek alignment with pharma to validate technologies, differentiate assets, and creatively partner to raise capital and de-risk future pipelines.
News & Content Room
Pipeline Innovation Partner
